Cargando…
How Do Anti-SARS-CoV-2 mRNA Vaccines Protect from Severe Disease?
COVID-19 pathogenesis develops in two phases. First, Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 spreads within the epithelial cells of the mucosa of upper and, possibly, lower respiratory tracts. While the virus dissemination can be controlled by an emerging adaptive host immune resp...
Autor principal: | Federico, Maurizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499329/ https://www.ncbi.nlm.nih.gov/pubmed/36142284 http://dx.doi.org/10.3390/ijms231810374 |
Ejemplares similares
-
Biological and Immune Responses to Current Anti-SARS-CoV-2 mRNA Vaccines beyond Anti-Spike Antibody Production
por: Federico, Maurizio
Publicado: (2022) -
mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
por: Jin, Yingqi, et al.
Publicado: (2022) -
The conundrum of current anti-SARS-CoV-2 vaccines
por: Federico, Maurizio
Publicado: (2021) -
Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021) -
Approved mRNA Vaccines for SARS-CoV-2
por: Faiman, Beth
Publicado: (2021)